Product image of Glycophos (Sodium Glycerophosphate Pentahydrate) supplied by GNH India

Glycophos

Active Ingredient:
Sodium Glycerophosphate Pentahydrate
Origin:
EU

Glycophos (Sodium Glycerophosphate Pentahydrate)

Glycophos is a prescription sodium glycerophosphate pentahydrate solution for injection. It contains the active ingredient sodium glycerophosphate pentahydrate in a sterile aqueous form for intravenous administration. Marketed in the European Union, Glycophos provides phosphate and sodium ions to support metabolic processes and electrolyte balance. The product is supplied as a ready‑to‑use injectable solution. It is intended for use under medical supervision and is stored according to manufacturer guidelines.

Manufacturer / TM Owner

Fresenius Kabi Italia S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Glycophos is used as an intravenous phosphate supplement in clinical settings where rapid replenishment of phosphate and sodium is required, particularly when oral supplementation is not feasible.

  • Correction of hypophosphatemia in hospitalized patients
  • Support during parenteral nutrition
  • Management of electrolyte disturbances associated with renal replacement therapy
  • Adjunct in cardiac surgery to maintain phosphate levels
  • Use in patients with severe burns or trauma to restore phosphate balance

Side Effects

Potential adverse effects of Glycophos may arise from its phosphate and sodium content or from infusion‑related reactions.

Common

  • Mild hyperphosphatemia
  • Transient hypernatremia
  • Injection site pain or erythema
  • Nausea
  • Headache

Serious

  • Severe hyperphosphatemia leading to calcium‑phosphate precipitation
  • Acute renal failure exacerbation
  • Severe electrolyte imbalance causing cardiac arrhythmia
  • Anaphylactic reaction to the solution

Precautions & Warnings

When prescribing Glycophos, clinicians should consider several precautions to minimize risk and ensure appropriate use.

  • Assess baseline serum phosphate, calcium, and sodium levels before administration
  • Avoid use in patients with severe hyperphosphatemia or hypercalcemia
  • Monitor renal function, especially in those with impaired clearance
  • Adjust infusion rate in patients at risk for fluid overload
  • Observe for signs of electrolyte imbalance during and after infusion
  • Use caution in patients with cardiac disease or hypertension

Avoid Interactions

Glycophos may interact with other medications or solutions administered intravenously, requiring attention to compatibility and cumulative electrolyte effects.

Avoid

  • Concurrent infusion of calcium‑containing solutions that may precipitate calcium phosphate
  • Co‑administration with other phosphate salts that could cause excessive phosphate load

Use with caution

  • Loop diuretics that alter sodium balance
  • ACE inhibitors or ARBs that affect renal handling of electrolytes
  • Medications that prolong QT interval, as electrolyte shifts may increase risk
  • Blood products containing citrate, which can bind calcium

Frequently Asked Questions

Glycophos contains sodium glycerophosphate pentahydrate, which dissociates to provide phosphate and sodium ions that participate in metabolic pathways and help maintain electrolyte balance.

Glycophos is supplied as a sterile solution for intravenous injection and is given under medical supervision, typically via a controlled infusion.

It is commonly used for rapid correction of hypophosphatemia, support during parenteral nutrition, electrolyte management in renal replacement therapy, and peri‑operative care such as cardiac surgery.

Baseline serum phosphate, calcium, sodium, and renal function tests are recommended to determine the need for supplementation and to set safe dosing parameters.

Glycophos provides phosphate directly into the bloodstream, allowing for faster correction of deficits, whereas oral supplements rely on gastrointestinal absorption, which can be slower or limited in certain patients.

Common side effects include mild hyperphosphatemia, transient hypernatremia, injection‑site discomfort, nausea, and headache.

Serious reactions include severe hyperphosphatemia with calcium‑phosphate precipitation, acute renal failure worsening, cardiac arrhythmias due to electrolyte imbalance, and anaphylactic responses.

Patients with existing severe hyperphosphatemia, hypercalcemia, or known hypersensitivity to the formulation should not receive Glycophos.

The solution should be stored according to the manufacturer’s instructions, typically at controlled room temperature, protected from light, and used before the expiration date.

Concurrent administration is generally avoided because calcium can precipitate with phosphate, potentially forming insoluble calcium‑phosphate complexes.

Regular monitoring of serum phosphate, calcium, sodium, and renal function is advised, along with observation for signs of electrolyte disturbance or infusion reactions.

Glycophos is marketed in the European Union; its regulatory status in the United States may differ and should be verified with local health authorities.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sodium Glycerophosphate Pentahydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT